

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10516381	
	Filing Date		2004-11-30	
	First Named Inventor	Guenther Eissner		
	Art Unit	1635		
	Examiner Name	Amy Hudson Bowman		
	Attorney Docket Number	021149-000001		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
/AB/	1	98/48843	WO		1998-11-05	Arsinur Burcoglu		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10516381
Filing Date	2004-11-30
First Named Inventor	Guenther Eissner
Art Unit	1635
Examiner Name	Amy Hudson Bowman
Attorney Docket Number	021149-000001

/AB/	1	International Search Report, corresponding to International Patent Application No. PCT/EP03/05753, dated 2003-11-20	<input type="checkbox"/>
	2	OSNAT BAIREY et al.; Clinical Severe Hepatic Venooclusive Disease During Induction Treatment of Acute Monoblastic Leukemia Managed with Defibrotide; American Journal of Hematology; 2002; pp. 281-284; Vol. 69; Wiley-Liss, Inc.	<input type="checkbox"/>
	3	P.G. RICHARDSON et al.; Multi-Institutional Phase II, Randomized Dose Finding Study of Defibrotide (DF) in Patients (pts) with Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post Stem Cell Transplantation (SCT): Promising Response Rate without Significant Toxicity in a High Risk Population; BLOOD; November 16, 2001; page 853a, XP008022856; Vol. 98, No. 11, Part 1; 43rd Annual Meeting of the American Society of Hematology, Part 1; Orlando, FL, USA; December 7-11, 2001; November 16, 2001; ISSN: 0006-4971 (ABSTRACT ONLY)	<input type="checkbox"/>
	4	N. MIRANDA et al.; Treatment of Hepatic Veno-Occlusive Disease (VOD) with Defibrotide: Results in 5 Stem Cell Transplant Recipients; BLOOD; November 15, 1999; page 359b, XP008022584; Vol. 94, No. 10, Suppl. 1 Part 2; 41st Annual Meeting of the American Society of Hematology; New Orleans, LA, USA; December 3-7, 1999; ISSN: 0006-4971 (ABSTRACT ONLY)	<input type="checkbox"/>
	5	B.E. SHAW et al.; The use of Defibrotide in the Management of Vascular Endothelial Complications (VOD/HUS/TTP) of Stem Cell Transplantation; BLOOD; November 15, 1999; page 608a, XP008022855; Vol. 94, No. 10, Supple. 1 Part 1; 41st Annual Meeting of the American Society of Hematology; New Orleans, LA, USA; December 3-7, 1999; ISSN: 0006-4971 (ABSTRACT ONLY)	<input type="checkbox"/>
	6	H.G. SAYER et al.; Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation - successful treatment with high-dose methylprednisolone and defibrotide; Journal of Cancer Research and Clinical Oncology; 2002; pp. 148-152; Vol. 128, No. 3.	<input type="checkbox"/>
	7	ROBERTO MAISANO et al.; Defibrotide in the Prevention of Venous Irritation by Vinorelbine Administration; Anticancer Research; 1997; pp. 2775-2778; Vol. 17.	<input type="checkbox"/>
	8	PAUL G. RICHARDSON et al.; Treatment of Severe Veno-Occlusive Disease with Defibrotide: Compassionate Use Results in Response without Significant Toxicity in a High-Risk Population; BLOOD; August 1, 1998; pp. 737-744; Vol. 92, No. 3.	<input type="checkbox"/>
	9	R. CHOPRA et al.; Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study; British Journal of Haematology; 2000; pp. 1122-1129; Vol. 111.	<input type="checkbox"/>
	10	HENING SCHRÖDER; Defibrotide Protects Endothelial Cells, but not L929 Tumour Cells, from Tumour Necrosis Factor- $\alpha$ -mediated Cytotoxicity; Journal of Pharmacy and Pharmacology; 1995; pp. 250-252; Vol. 47.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

Add

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10516381
Filing Date	2004-11-30
First Named Inventor	Guenther Eissner
Art Unit	1635
Examiner Name	Amy Hudson Bowman
Attorney Docket Number	021149-000001

**EXAMINER SIGNATURE**

Examiner Signature	/Amy Bowman/	Date Considered	01/21/2009
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.